Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057810 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 837
- Enrollment target
- 20
- Study locations
NCT01057810: Completed Phase 3 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
NCT01057810 is a Phase 3 study of Prostate Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 837 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01057810, a Phase 3 study of Prostate Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 837 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo
Primary Outcome
OS was defined as the time from the date of randomization until the date of death. For participants without documentation of death, OS was censored at the last date the participant was known to be alive.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ipilimumab
Study Locations (20)
Florida
- Lynn Cancer Institute Center For Hematology-Oncology - Boca Raton
- Baptist Cancer Institute - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Md Anderson Cancer Center Orlando - Orlando
- Hematology Oncology Associates Of The Treasure Coast - Port Saint Lucie
California
- Desert Hematology Oncology - Rancho Mirage
- Southern California Permanente Medical Group - San Diego
- Pacific Hematology Oncology Associates - San Francisco
Georgia
- Northside Hospital - Atlanta
- Georgia Regents University - Augusta
- Gwinnett Hospital System Inc. - Lawrenceville
Arizona
- Pinnacle Oncology Hematology - Scottsdale
- Arizona Cancer Center - Tucson
Illinois
- University Of Chicago - Chicago
- Cancer Care Specialists Of Central Illinois - Decatur
Alaska
- Alaska Clinical Research Center, Llc - Anchorage
District of Columbia
- George Washington University - Washington D.C.
Hawaii
- Straub Clinic And Hospital - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 837 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
What the finished NCT01057810 record still lists
NCT01057810 is an interventional study that assigns participants to a tested intervention. The registered 837 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01057810 names 20 study sites across 10 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01057810 about?
NCT01057810 is a clinical study titled "Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer". The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo
What is the current status of trial NCT01057810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 837 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01057810 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01057810?
The interventions under investigation include: Placebo (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT01057810?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01057810 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01057810's enrollment target sits among peer trials
837 75th of 735 higher than 661 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422550 · 837 participants
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia